CDK4 6 Inhibitors: Changing the Early Breast Cancer Landscape

Join Dr. Francisco Javier Esteva in a journey through the innovative world of early-stage breast cancer treatment. In this episode, he uncovers the significant influence of CDK4/6 inhibitors, examining the mechanism and efficacy of FDA-approved drugs Palbociclib (Ibrance), Ribociclib (Kisqali), and Abemaciclib (Verzenio). As a medical oncologist with a specialty in breast cancer, Dr. Esteva offers a deep dive into the MONARCH-E and NATALEE trials, presenting insights on how these therapies are revolutionizing the management of patients with early-stage, hormone receptor-positive, HER2-negative breast cancer. Whether you're a healthcare professional or an individual touched by cancer, this video is a valuable resource for understanding the advancements in cancer care.
#Verzenio #Kisqali #Ibrance #Cancer
About:
Cancer Treatment Updates is a deep-dive podcast focusing on cancer biology, research and treatment. It features topics including molecular classification of cancer and its impact on prognosis, predictive markers, chemotherapy, endocrine therapy, targeted therapy, immunotherapy, surgery, radiation therapy, risk assessment, survivorship and much more.
Dr. Francisco Javier Esteva is a medical oncologist based in New York City. He currently serves as Chief of Hematology and Medical Oncology at Lenox Hill Hospital, an academic institution of Northwell Health. Opinions are his own, and not reflective of the opinions or views of his employer.
Learn more: www.cancertreatmentupdates.com
Follow Dr. Esteva:
Instagram / dresteva
Facebook www.facebook.c...
Twitter (X) / cancerrxupdates
TikTok / dresteva
LinkedIn / franciscoesteva
Google Scholar: scholar.google...
UA-cam / @cancertreatmentupdates
Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this visual podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. Please review our Terms of Use: www.cancertrea....

[@qtbzubz]

very informative, thanks

[@cancertreatmentupdates]

Glad it was helpful!

[@user-vu7vr7lb1j]

Thank you for this information
I was diagnosed in 2022 with bilateral, multifocal ILC. Ki67 of 30% node negative . Is it too late for me to add either vezenio or kisqali to my daily letrozole pill? Is there a time limit on how soon after diagnosis this therapy must be started?

[@cancertreatmentupdates]

Good question! Please discuss with your medical oncologist.

[@cancertreatmentupdates]

This is an important question. Please discuss with your oncologist. Each person is different and I can’t give you any medical advice.